GE Healthcare Biopharma Services

Pharma Services

NeoGenomics offers lab services for oncology clinical trials

Learn more 
Clarient

Clarient Client Resources

For current Clarient clients only, access your Clarient resources here.

Browse Resources

News

Welcome to our new website!

Your resource for the combined NeoGenomics
and Clarient companies
Image%20Alt%20Text

PD-L1 Updates

SP142 for bladder cancer now available

Learn more

Webinar:
PD-L1 testing for
anti-PD-1 Therapy

Presented by:
Neal Goldstein, MD
Director of Surgical Pathology for NeoGenomics/Clarient
Thursday, July 21, 2016
11:00 am PDT / 2:00 pm EDT

Join us

New Tests

Ventana PD-L1 (SP142) Assay, an FDA approved complementary diagnostic in metastatic urothelial carcinoma.

Indicated as an aid in identifying patients most likely to benefit from TECENTRIQ®

PD-L1, 142 (FDA) TECENTRIQ®

Learn more

Comprehensive detection of sarcoma transocations by next-gen sequencing to enhance diagnosis, subclassification, and treatment

Learn more

NGS Comprehensive Sarcoma Fusion Profile

Targeted next-gen sequencing panel that detects significant translocations in the genes NTRK1, NTRK3, and RET

Learn more

NGS Thyroid Fusion Profile